Immunohistochemical expression of extracellular matrix metalloproteinase inducer (EMMPRIN) in normal oral mucosa, oral epithelial dysplasia and oral squamous cell carcinoma

Arora, Manika; Mane, Deepa

doi:10.4103/jomfp.jomfp_129_17

Cited by 6 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Stromal cells include fibroblasts, macrophages, and vascular endothelial cells that secrete MMPs into the extracellular space [ 28 ]. The extracellular MMP inducer (EMMPRIN) stimulates MMP synthesis in stromal fibroblasts at early stages of tumorigenesis, and EMMPRIN expression also correlates with the grade of OED patient samples [ 29 ]. MMP-9 expression and tumor vascularity progressively increase from normal mucosa to OED, indicating an additional pro-angiogenic role of MMPs in early tumor formation [ 24 ].…”

Section: Extracellular and Cell Surface Biomarkersmentioning

confidence: 99%

Molecular Biomarkers of Malignant Transformation in Head and Neck Dysplasia

Ranganath

Feng

Franco

et al. 2022

Cancers

View full text Add to dashboard Cite

Head and neck squamous cell carcinoma (HNSCC) and its treatments are associated with substantial morbidity, often resulting in cosmetic deformity and loss of physiologic functions including speech and swallowing. Despite advancements in treatment, 5-year survival rates for mucosal malignancies remain below 70%. Effective prevention of HNSCC demands an understanding of the molecular pathways of carcinogenesis. Specifically, defining features of pre-cancerous dysplastic lesions that indicate a better or worse prognosis is necessary to help identify patients who are likely to develop a carcinoma and allow a more aggressive approach to management. There remains a need for identification of biomarkers that can provide both early prognostic and predictive value in clinical decision-making by serving as both therapeutic targets as well as predictors of therapy response. Here, we comprehensively review the most frequently altered molecular biomarkers of malignant transformation in head and neck dysplasia. These markers are involved in a wide range of cellular processes in head and neck carcinogenesis, including extracellular matrix degradation, cell motility and invasion, cell–cell adhesion, solute transport, immortalization, metabolism, the cell cycle and apoptosis, transcription, and cell signaling.

show abstract

Section: Extracellular and Cell Surface Biomarkersmentioning

confidence: 99%

Molecular Biomarkers of Malignant Transformation in Head and Neck Dysplasia

Ranganath

Feng

Franco

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Higher expression was found in clinical stage III compared to stage I/II and was associated with aggressiveness of tumor bone cells [113]. A significant association between the expression of CD147 protein and oral squamous carcinoma (OSCC) stage was reported in a cohort of 100 tissue blocks [114]. Our previous studies in OSCC tumors demonstrated increased expression of CD147 compared to dysplastic lesions.…”

Section: Cd147 As a Prognostic Biomarkermentioning

confidence: 99%

CD147 Is a Promising Target of Tumor Progression and a Prognostic Biomarker

Landras

Moura

Jouenne

et al. 2019

Cancers

View full text Add to dashboard Cite

Microenvironment plays a crucial role in tumor development and progression. Cancer cells modulate the tumor microenvironment, which also contribute to resistance to therapy. Identifying biomarkers involved in tumorigenesis and cancer progression represents a great challenge for cancer diagnosis and therapeutic strategy development. CD147 is a glycoprotein involved in the regulation of the tumor microenvironment and cancer progression by several mechanisms—in particular, by the control of glycolysis and also by its well-known ability to induce proteinases leading to matrix degradation, tumor cell invasion, metastasis and angiogenesis. Accumulating evidence has demonstrated the role of CD147 expression in tumor progression and prognosis, suggesting it as a relevant tumor biomarker for cancer diagnosis and prognosis, as well as validating its potential as a promising therapeutic target in cancers.

show abstract

“…It has been reported that variations in EMMPRIN glycosylation are also associated with multidrug resistance in human leukemia ( 23 ). Furthermore, EMMPRIN is highly expressed in the malignant tumor tissues ( 24 , 25 ) involved in human gliomas ( 26 , 27 ), suggesting that it may play roles in the progression of malignant gliomas.…”

Section: Introductionmentioning

confidence: 99%

Inhibition of EMMPRIN by microRNA‑124 suppresses the growth, invasion and tumorigenicity of gliomas

et al. 2021

View full text Add to dashboard Cite

MicroRNAs (miR) are a group of non-coding, small RNAs, 18-20 nucleotides in length, that are frequently involved in the development of a variety of different types of cancer, including glioma, which is a type of severe tumor in the brain. Previous studies reported that miR-124 levels were downregulated in glioma specimens; however, the potential role of miR-124 in glioma currently remains unclear. The present study performed experiments, including dual-luciferase reporter assay (DLRA), MTT assay, transwell assay and flow cytometry, with the aim of elucidating the molecular mechanism of miR-124 in glioma. The results indicated that miR-124 expression was decreased in glioma tissues, accompanied by the increased expression of extracellular matrix metalloproteinase inducer (EMMPRIN). The expression of EMMPRIN was inhibited by miR-124 transfection. The DLRA results revealed that EMMPRIN directly targets miR-124. Furthermore, upon overexpression of miR-124 in the U87 cells, cell proliferation was significantly inhibited, apoptosis was increased, and cell migration and invasion were decreased. Furthermore, tumor growth was blocked by miR-124 in mice. Based on these results, the present study concluded that miR-124 is critical for amelioration of glioma by targeting EMMPRIN, thereby acting as a tumor suppressor. Thus, miR-124/EMMPRIN constitutes a plausible basis for the treatment of glioma.

show abstract

Immunohistochemical expression of extracellular matrix metalloproteinase inducer (EMMPRIN) in normal oral mucosa, oral epithelial dysplasia and oral squamous cell carcinoma

Cited by 6 publications

References 13 publications

Molecular Biomarkers of Malignant Transformation in Head and Neck Dysplasia

Molecular Biomarkers of Malignant Transformation in Head and Neck Dysplasia

CD147 Is a Promising Target of Tumor Progression and a Prognostic Biomarker

Inhibition of EMMPRIN by microRNA‑124 suppresses the growth, invasion and tumorigenicity of gliomas

Contact Info

Product

Resources

About